Aino Health AB

As of June 30, 2026, Aino Health AB carries a market capitalization of 39.69M, placing it among publicly traded companies globally. Its enterprise value stands at 37.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Aino Health AB has 204.57M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.69, and the price-to-book ratio stands at -3.50.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 37.77M versus a market cap of 39.69M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Aino Health AB maintains a current ratio of 0.49, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -159.03, reflecting losses generated across the asset base. The company generates approximately 1.29M in revenue per employee across its workforce of 18.25, a quick read on workforce productivity versus industry peers.

As of the close on October 21, 2026, Aino Health AB's stock has declined approximately 17.31% over the past 52 weeks. The 50-day moving average sits at 0.20, while the 200-day moving average is 0.17.

Over the twelve months ended June 30, 2026, Aino Health AB generated 23.50M in revenue and converted that into -9.79M in net income, yielding earnings per share of -0.05. EBITDA reached -6.02M, while operating income came in at -8.90M.

These figures are as of June 30, 2026. Total book value stands at -11.33M, with working capital of -4.17M providing operational flexibility.

Aino Health AB produced -6.03M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Aino Health AB posted a gross margin of 92.33, reflecting its pricing power and cost economics. The operating margin of -37.87 and net profit margin of -41.64 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -15.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -18.20, meaning Aino Health AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Aino Health AB's most recent stock split took place on June 5, 2024 with a 119:177 split ratio.